Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Paper Chase #3 | CV Safety of Febuxostat

Andrew Buelt, DO and Joe Weatherly, DO
00:00
05:14
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol.

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
All Risk, No Reward Full episode audio for MD edition 187:18 min - 88 MB - M4AHippo PC RAP July 2018 Written Summary 362 KB - PDF